Naltrexone linked to reduction in pain in fibromyalgia

February 12, 2013
Naltrexone linked to reduction in pain in fibromyalgia
Low-dose naltrexone treatment is associated with significant reductions in pain in patients with fibromyalgia, according to a study published in the February issue of Arthritis & Rheumatism.

(HealthDay)—Low-dose naltrexone treatment is associated with significant reductions in pain in patients with fibromyalgia, according to a study published in the February issue of Arthritis & Rheumatism.

Jarred Younger, Ph.D., from the Stanford University School of Medicine in Palo Alto, Calif., and colleagues conducted a crossover study involving 31 women with who were randomly assigned to a four-week placebo stage and a 12-week active phase comprising 4.5 mg/day of naltrexone. Daily levels of pain were assessed.

The researchers found that baseline pain was significantly reduced in patients taking low-dose naltrexone versus placebo (reduction of 28.8 percent versus 18.0 percent). There was also significant improvement in general satisfaction with life and mood in patients taking naltrexone, although there was no improvement in fatigue or sleep. The response rate, as assessed by significant reductions in pain plus a significant reduction either fatigue or sleep problems, was significantly higher for low-dose naltrexone than placebo (32 versus 11 percent). Naltrexone was as well tolerated as placebo and there were no serious side effects.

"Our replicated observation that low-dose naltrexone affects levels of , together with the low cost and tolerable nature of low-dose , makes it a promising target for future investigation," Younger and colleagues conclude.

Explore further: Use of naltrexone reduces inflammation in Crohn's patients

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Use of naltrexone reduces inflammation in Crohn's patients

May 19, 2011
Naltrexone reduced inflammation in Crohn's patients in a research study at Penn State College of Medicine.

Cannabinoid formulation benefits opioid-refractory pain

June 13, 2012
(HealthDay) -- A novel cannabinoid formulation, nabiximols, is safe and effective for patients with advanced cancer and opioid-refractory pain, especially at a low-dose, according to a study published in the May issue of ...

Fatigue not a factor in fibromyalgia pain, study says

April 26, 2012
(HealthDay) -- Poor sleep is not a significant predictor of pain intensity and duration in patients with fibromyalgia, a new study says.

Study sheds light on pain pill abuse

September 26, 2012
A study by a team of University of Kentucky researchers has shed new light on the potential habit-forming properties of the popular pain medication tramadol, in research funded by the National Institute on Drug Abuse. The ...

Asians fighting alcoholism may benefit from new study

September 27, 2011
(Medical Xpress) -- New UCLA psychology research indicates that Asians who are struggling with alcoholism may benefit especially from naltrexone, one of three medications approved by the U.S. Food and Drug Administration ...

Recommended for you

Researchers developing new tool to distinguish between viral, bacterial infections

July 28, 2017
Antibiotics are lifesaving drugs, but overuse is leading to one of the world's most pressing health threats: antibiotic resistance. Researchers at the University of Rochester Medical Center are developing a tool to help physicians ...

Finish your antibiotics course? Maybe not, experts say

July 27, 2017
British disease experts on Thursday suggested doing away with the "incorrect" advice to always finish a course of antibiotics, saying the approach was fuelling the spread of drug resistance.

Co-infection with two common gut pathogens worsens malnutrition in mice

July 27, 2017
Two gut pathogens commonly found in malnourished children combine to worsen malnutrition and impair growth in laboratory mice, according to new research published in PLOS Pathogens.

Phase 3 trial confirms superiority of tocilizumab to steroids for giant cell arteritis

July 26, 2017
A phase 3 clinical trial has confirmed that regular treatment with tocilizumab, an inhibitor of interleukin-6, successfully reduced both symptoms of and the need for high-dose steroid treatment for giant cell arteritis, the ...

A large-scale 'germ trap' solution for hospitals

July 26, 2017
When an infectious airborne illness strikes, some hospitals use negative pressure rooms to isolate and treat patients. These rooms use ventilation controls to keep germ-filled air contained rather than letting it circulate ...

Researchers report new system to study chronic hepatitis B

July 25, 2017
Scientists from Princeton University's Department of Molecular Biology have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.